Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{ [4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4- yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.